




"Express Mail" Label No. EL 889371863 US
Date of Deposit April 10, 2003

PATENT

Attorney Docket No.: 20695C-005900US
Client Ref. No.: 237.00

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: 
Maisie C. Livengood

RECEIVED
APR 16 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHEIFLINGER *et al.*

Application No.: 09/661,992

Filed: September 14, 2000

For: FACTOR IX/FACTOR IXa
ACTIVATING ANTIBODIES AND
ANTIBODY DERIVATIVES

Examiner: DeCloux, Amy M.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Mail Stop SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed February 6, 2003, to Michael C. Schiffer at Baxter Healthcare Corporation, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

SCHEIFLINGER *et al.*
Application No.: 09/661,992
Page 2

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 14 of this paper.